372 related articles for article (PubMed ID: 32666604)
1. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD.
Weber M; Mera P; Casas J; Salvador J; Rodríguez A; Alonso S; Sebastián D; Soler-Vázquez MC; Montironi C; Recalde S; Fucho R; Calderón-Domínguez M; Mir JF; Bartrons R; Escola-Gil JC; Sánchez-Infantes D; Zorzano A; Llorente-Cortes V; Casals N; Valentí V; Frühbeck G; Herrero L; Serra D
FASEB J; 2020 Sep; 34(9):11816-11837. PubMed ID: 32666604
[TBL] [Abstract][Full Text] [Related]
2. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation.
Orellana-Gavaldà JM; Herrero L; Malandrino MI; Pañeda A; Sol Rodríguez-Peña M; Petry H; Asins G; Van Deventer S; Hegardt FG; Serra D
Hepatology; 2011 Mar; 53(3):821-32. PubMed ID: 21319201
[TBL] [Abstract][Full Text] [Related]
3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
4. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation.
Wu X; Zheng H; Yang R; Luan X; Zhang L; Jin Q; Jin Y; Xue J
Am J Physiol Endocrinol Metab; 2019 Sep; 317(3):E436-E445. PubMed ID: 31211621
[TBL] [Abstract][Full Text] [Related]
5. Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet.
Zheng F; Cai Y
Lipids Health Dis; 2019 Jan; 18(1):6. PubMed ID: 30611282
[TBL] [Abstract][Full Text] [Related]
6. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
8. Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis.
Monsénégo J; Mansouri A; Akkaoui M; Lenoir V; Esnous C; Fauveau V; Tavernier V; Girard J; Prip-Buus C
J Hepatol; 2012 Mar; 56(3):632-9. PubMed ID: 22037024
[TBL] [Abstract][Full Text] [Related]
9. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
11. Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases.
Dewidar B; Mastrototaro L; Englisch C; Ress C; Granata C; Rohbeck E; Pesta D; Heilmann G; Wolkersdorfer M; Esposito I; Reina Do Fundo M; Zivehe F; Yavas A; Roden M
EBioMedicine; 2023 Aug; 94():104714. PubMed ID: 37454552
[TBL] [Abstract][Full Text] [Related]
12. Liver-specific deletion of IGF2 mRNA binding protein-2/IMP2 reduces hepatic fatty acid oxidation and increases hepatic triglyceride accumulation.
Regué L; Minichiello L; Avruch J; Dai N
J Biol Chem; 2019 Aug; 294(31):11944-11951. PubMed ID: 31209109
[TBL] [Abstract][Full Text] [Related]
13. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.
Lu H; Yuan X; Zhang Y; Han M; Liu S; Han K; Liang P; Cheng J
Biomed Pharmacother; 2020 Sep; 129():110347. PubMed ID: 32535386
[TBL] [Abstract][Full Text] [Related]
14. REDD1 deficiency protects against nonalcoholic hepatic steatosis induced by high-fat diet.
Dumas K; Ayachi C; Gilleron J; Lacas-Gervais S; Pastor F; Favier FB; Peraldi P; Vaillant N; Yvan-Charvet L; Bonnafous S; Patouraux S; Anty R; Tran A; Gual P; Cormont M; Tanti JF; Giorgetti-Peraldi S
FASEB J; 2020 Apr; 34(4):5046-5060. PubMed ID: 32043636
[TBL] [Abstract][Full Text] [Related]
15. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
16. Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver.
Tobita H; Sato S; Yazaki T; Mishiro T; Ishimura N; Ishihara S; Kinoshita Y
Mol Med Rep; 2018 May; 17(5):6840-6846. PubMed ID: 29512720
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.
Vida M; Gavito AL; Pavón FJ; Bautista D; Serrano A; Suarez J; Arrabal S; Decara J; Romero-Cuevas M; Rodríguez de Fonseca F; Baixeras E
Dis Model Mech; 2015 Jul; 8(7):721-31. PubMed ID: 26035386
[TBL] [Abstract][Full Text] [Related]
18. Aerobic capacity and hepatic mitochondrial lipid oxidation alters susceptibility for chronic high-fat diet-induced hepatic steatosis.
Morris EM; Meers GM; Koch LG; Britton SL; Fletcher JA; Fu X; Shankar K; Burgess SC; Ibdah JA; Rector RS; Thyfault JP
Am J Physiol Endocrinol Metab; 2016 Oct; 311(4):E749-E760. PubMed ID: 27600823
[TBL] [Abstract][Full Text] [Related]
19. Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice.
Ohashi T; Nakade Y; Ibusuki M; Kitano R; Yamauchi T; Kimoto S; Inoue T; Kobayashi Y; Sumida Y; Ito K; Nakao H; Umezawa K; Yoneda M
PLoS One; 2019; 14(1):e0210068. PubMed ID: 30689650
[TBL] [Abstract][Full Text] [Related]
20. Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.
Secor JD; Cho BS; Yu LJ; Pan A; Ko VH; Dao DT; Feigh M; Anez-Bustillos L; Fell GL; Fraser DA; Gura KM; Puder M
Lipids; 2022 Jul; 57(4-5):241-255. PubMed ID: 35778847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
